A groundbreaking study reveals that the over-the-counter supplement nicotinamide riboside can significantly improve walking ability in patients with peripheral artery disease (PAD). Participants in a six-month trial experienced a remarkable increase in walking distance, while those taking a placebo saw a decline. This affordable and accessible supplement offers new hope for millions living with this debilitating condition, potentially revolutionizing treatment options.

#nicotinamide_riboside #peripheral_artery_disease #PAD #clinical_trial #vitamin_B3

McDermott, M.M., Martens, C.R., Domanchuk, K.J. et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun 15, 5046 (2024). https://doi.org/10.1038/s41467-024-49092-5

nicotinamide riboside, peripheral artery disease, PAD, walking endurance, clinical trial, NAD, energy metabolism, muscle function, blood flow, DNA repair, randomized controlled trial, placebo, gastrocnemius, satellite cells, supplement, vitamin B3, over-the-counter, chronic leg disease, treatment options, exercise, rehabilitation, patient outcomes, quality of life, cost-effectiveness, healthcare, geriatrics, cardiology